Erica Bial
Medical Director, Clinical Development Pain Vertex Pharmaceuticals
Dr. Bial is a dual board-certified physician in Pain Management and Internal Medicine with over 20 years of clinical experience prior to her joining Vertex. She specialises in non-opioid pain therapies, neuropathic pain disorders and spine pain, with extensive expertise across pharmaceutical, interventional and device-based approaches. Prior to joining Vertex, she served as Principal Investigator for Phase II and III clinical trials, and now offers insight as Medical Director in Clinical Development on the Acute Pain team at Vertex. Dr. Bial holds advanced qualifications in Pain Science and Pain Research. She is also an award-winning medical educator and former Assistant Professor of Neurosurgery at Tufts University School of Medicine, Instructor of Pain Medicine at Harvard Medical School, and lecturer at Boston University School of Medicine, and was Honorable Mention for the Schwartz Center 2021 Compassionate Caregiver of the Year Award for her work in pain medicine in response to the COVID-19 crisis.
Seminars
This workshop will explore practical strategies to improve assay sensitivity in pain trials by reducing placebo response, refining patient selection and optimizing endpoint design. Attendees will discuss how study design choices can strengthen efficacy signals, improve regulatory confidence and increase the likelihood of clinical success across diverse pain populations.
Key Topics Covered:
- How can patient selection criteria, trial design and site execution be optimized to reduce placebo response and improve signal detection in chronic pain studies?
- What role do biomarkers, patient-reported outcomes and clinically meaningful endpoints play in distinguishing true treatment effects from placebo-driven responses?
- How should crossover, parallel-group and other trial designs be applied across acute, chronic and paediatric pain indications to maximize sensitivity and relevance?
- What evolving regulatory approaches, including historical controls and single pivotal trial pathways, could streamline development while maintaining robust efficacy and safety standards?
